初步接触与保密协议签订

Good morning, Ms. Chen. Thank you for taking the time to meet with us today. As we discussed briefly, our company, Nexus Corp, has been very impressed with AlphaTech's innovative solutions in the biotech sector.

Good morning, Mr. Davis. The pleasure is ours. We're certainly proud of what we've built at AlphaTech. What specifically brought about this interest from Nexus Corp?

Well, we believe there's significant synergy between our respective business models, particularly in terms of market reach and R&D capabilities. We see a strong potential for a strategic partnership, or even a full acquisition, that could benefit both our stakeholders.

I see. An acquisition is a significant consideration, of course. To explore this further and for us to truly understand the scope of your interest, we'd need to delve into some confidential information.

Absolutely. That's precisely why we’ve prepared a standard Non-Disclosure Agreement for your review. It outlines the terms under which we can exchange sensitive data and ensures confidentiality throughout our discussions.

Thank you. We appreciate you being proactive on that. My legal team will need to review it thoroughly. What's your proposed timeline for this initial phase?

Ideally, we’d hope to have the NDA signed within the next week. That would allow us to move forward with a preliminary information exchange and deeper due diligence, perhaps scheduling some follow-up meetings with your key department heads.

Understood. I'll ensure our team prioritizes the review of the NDA. We'll be in touch by the end of this week at the latest with our feedback. Thank you again for coming, Mr. Davis.